Hemagen Diagnostics Inc の最大収益セグメントは French Retail and Private Banking で、最新の利益発表における収益は 7,983,000,000 です。地域別に見ると、France が Hemagen Diagnostics Inc の主要市場であり、収益は 11,118,000,000 です。
Hemagen Diagnostics Incは収益を上げていますか?
いいえ、最新の財務諸表によると、Hemagen Diagnostics Incの純損失は$0です。
Hemagen Diagnostics Incに負債はありますか?
はい、Hemagen Diagnostics Incの負債は5です。
Hemagen Diagnostics Incの発行済株式数は何株ですか?
Hemagen Diagnostics Incの総発行済株式数は15.5株です。
主要データ
前終値
$0.0002
始値
$0.0001
当日レンジ
$0.0001 - $0.015
52週レンジ
$0.0001 - $0.0201
取引高
50.0K
平均取引高
346
配当利回り
--
1株当たり利益(TTM)
-0.06
時価総額
$3.1K
HMGNとは何ですか?
Hemagen Diagnostics, Inc. is a biotechnology company. The company is headquartered in Columbia, Maryland and currently employs 15 full-time employees. The firm is primarily focused on Veterinary Clinical Diagnostics. The company is also focused on VIRGO, its Human Clinical Diagnostic line of autoimmune and infectious disease products. The firm develops, manufactures and markets a range of test kits used to aid in the diagnosis of certain autoimmune and infectious diseases. The Company’s autoimmune product portfolio includes Hemagen DNA Kit, Hemagen Rheumatoid Factor Kit, VIRGO AMA IgG, VIRGO ANA/Hep-2 IgG, VIRGO Anti-nDNA IgG, VIRGO cANCA (PR-3) Kit, VIRGO dsDNA Kit, VIRGO ENA Screen 6 Kit, VIRGO ENA Screening, VIRGO ENA Series, VIRGO pANCA myeloperoxidase (MPO) Kit and VIRGO Rheumatoid Factor Kit. The company offers various products for infectious disease, which includes VIRGO C. trach IgG, VIRGO CMV IgG and VIRGO epstein-barr virus (EBV)- viral capsid antigen (VCA) IgG. Its products are used in laboratories, hospitals and blood banks around the world.